Current mRNA therapies face challenges in delivering genetic payloads to specific tissues and cell types, often resulting in limited efficacy and potential off-target effects. Existing delivery technologies struggle to efficiently target cells beyond the liver, hindering the development of mRNA-based treatments for a wide range of diseases.

Nuntius Therapeutics develops programmable mRNA therapies using proprietary, non-immunogenic nanocarriers designed to enhance delivery efficiency to a wide range of tissues and cell types. The company leverages machine learning models to predict carrier quality and performance, guiding the selection of optimal candidates from a library of millions of distinct carriers. Nuntius also focuses on superior nucleic acid engineering to design mRNA with enhanced protein expression levels compared to existing mRNA therapeutics. This approach enables the development of transformative mRNA therapies for life-threatening conditions, including cancer, lung diseases, and neurodegenerative disorders.

Proprietary nanocarriers for targeted delivery of mRNA to specific tissues and cell types

Non-immunogenic nanocarriers to minimize adverse immune responses

Machine learning models to predict carrier quality and performance

Superior nucleic acid engineering for enhanced protein expression levels

Scalable nanocarrier production for efficient manufacturing

The primary target audience includes pharmaceutical companies and research institutions focused on developing mRNA-based therapeutics for cancer, lung diseases, and neurodegenerative disorders.